September 21, 2021
Daiichi Sankyo and AstraZeneca said on September 16 that the first patient has been dosed in a Chinese PII study for the antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) for a third-line treatment for HER2 positive gastric cancer. The trial,...read more